UARK 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE

This study has been completed.
Sponsor:
Information provided by:
University of Arkansas
ClinicalTrials.gov Identifier:
NCT00577512
First received: December 18, 2007
Last updated: April 19, 2011
Last verified: April 2011

December 18, 2007
April 19, 2011
April 2007
April 2009   (final data collection date for primary outcome measure)
Number of Subjects Treated With (HD DTPACE Obtain a Complete Response or Near Complete Response That Lasts for 6 Months or Longer. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
To find out how many subjects treated with high dose DTPACE and Etoposide. (HD DTPACE) on this protocol will have a complete response or near complete response that lasts for 6 months or longer. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00577512 on ClinicalTrials.gov Archive Site
In Subjects Achieving a Response, to Find Out How Long the Response Will Last. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
UARK 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE
UARK 2006-32: Phase II Study of Rapidly Recycled High Dose DTPACE (HD-DTPACE) for Untreated or Previously Treated, High-Risk Multiple Myeloma (MM)

This study is being done in an attempt to improve the remission rate and the survival time for subjects with high-risk myeloma. It is hoped that by giving higher doses of commonly used chemotherapy drugs and by giving courses closer together (before the myeloma comes back or gets worse), subjects in this study will have better outcomes.

This study has the following goals:

  • To find out how many subjects treated with high dose DTPACE (Dexamethasone, Thalidomide, CisPlatin, Adriamycin, Cyclophosphamide, and Etoposide. (HD DTPACE) on this protocol will have a complete response or near complete response that lasts for 6 months or longer.
  • In subjects achieving a response, to find out how long the response will last.
  • To learn more about the side effects of this treatment.

Up to 75 subjects, male or female, age 18 and older, regardless of race or ethnicity, will participate in this study at UAMS only.

The treatment in this study is divided into 3 parts

  • High dose DTPACE and stem cell collection if you do not already have sufficient stem cells stored.
  • High dose DTPACE and stem cell re-infusion.
  • Velcade, Thalidomide, Dexamethasone (sometimes known as VTD) Maintenance therapy.
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Multiple Myeloma
Drug: DTPACE
  • Dexamethasone 200 mg IVPB Days 1-7
  • Thalidomide 200 mg PO Days 1-7
  • Cisplatin 15mg/m2 Days 1-4 (modify for renal insufficiency)
  • Adriamycin 15 mg/m2 Days 1-4
  • Cyclophosphamide 600 mg/m2 Days 1-4
  • Etoposide 60 mg/m2 Days 1-4
Experimental: HD DTPACE
DTPACE
Intervention: Drug: DTPACE
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
4
April 2009
April 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with multiple myeloma, treated or untreated, with the presence of one or more of the high risk features as defined below.

High risk by gene expression profiling at any time prior to enrollment:

  1. PROLIFERATION signature, MMSET/FGFR3, c-MAF/MAF-B groups or
  2. High risk score based on MIRT 70 gene model.

    • Abnormal metaphase cytogenetics at any time prior to enrollment, or
    • LDH > 250 IU/L (upper limit normal) at any time prior to enrollment

      • Zubrod ≤ 2, unless due to symptoms of MM.
      • Patients must be < 75 years of age at the time of registration.
      • Patient must have signed an IRB-approved informed consent and understand the investigational nature of the study.
      • Negative serology for HIV.
      • Patients must not have a history of chronic obstructive or chronic restrictive pulmonary disease. Patients must have adequate pulmonary function studies > 50% of predicted on mechanical aspects (FEV1, FVC, etc) and diffusion capacity (DLCO) > 50% of predicted. Patients unable to complete pulmonary function tests because of myeloma-related chest pain, must have a high resolution CT scan of the chest and must also have acceptable arterial blood gases defined as P02 greater than 70.
      • Patients with recent (< 6 months) myocardial infarction, unstable angina, difficult to control congestive heart failure, uncontrolled hypertension, or difficult to control cardiac arrhythmias are ineligible. Ejection fraction by ECHO or must be > 40% and must be performed within 60 days prior to registration, unless the patient has received chemotherapy within that period of time (dexamethasone and thalidomide excluded), in which case the LVEF must be repeated.
      • No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease free for at least three years. Prior malignancy is acceptable provided there has been no evidence of disease within the three-year interval or if the malignancy is considered much less life threatening than the myeloma.
      • Pregnant or nursing women may not participate. Women of childbearing potential must have a negative pregnancy documented within one week of registration. Women/men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
      • Patients must be able to receive full doses of HD-DTPACE, in the opinion of the treating investigator, with the exception that patients with serum creatinine > 1.5 mg/dL will receive modified doses of cisplatin.

Exclusion Criteria:

  • Fever or active infection requiring intravenous antibiotics within 72 hours from baseline.
  • Liver function abnormalities with total bilirubin more than twice the upper limit of normal or AST/ALT more than three times the upper limit of normal.
  • Severe renal dysfunction, defined as a creatinine > 3mg/dl or a creatinine clearance of <30ml/min.
  • Platelet count < 30,000/mm3, or ANC < 1,000/μl.
  • Clinically significant hepatic dysfunction as noted by direct bilirubin or AST >3 times the upper normal limit or clinically significant concurrent hepatitis.
  • New York Hospital Association (NYHA) Class III or Class IV heart failure.
  • Poorly controlled hypertension, diabetes mellitus, or other serious medical illness or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol.
  • Prior adriamycin exposure > 450 mg/m2.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00577512
2006-32
No
Frits van Rhee, MD, PhD, University of Arkansas for Medical Sciences
University of Arkansas
Not Provided
Principal Investigator: Frits van Rhee, MD, PhD University of Arkansas
University of Arkansas
April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP